CEO Markus Warmuth (Monte Rosa)

Monte Rosa rakes in $96M Se­ries B as it pre­pares 'mol­e­c­u­lar glue' plat­form for IND-en­abling stud­ies

About four months af­ter com­plet­ing an ex­ten­sion to its Se­ries A, Monte Rosa Ther­a­peu­tics is putting its next foot for­ward with an­oth­er heap of cash.

The Boston-based biotech is back with $96 mil­lion in Se­ries B fi­nanc­ing with a goal to get its lead pro­gram ready for IND-en­abling stud­ies by the end of the year. Though Monte Rosa is keep­ing its spe­cif­ic tar­get a se­cret for now, the com­pa­ny has been re­search­ing how to uti­lize its pro­tein degra­da­tion tech­nol­o­gy in breast can­cer and non-small cell lung can­cer, among oth­er ar­eas.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.